

Vera Magistroni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5905777/publications.pdf>

Version: 2024-02-01

27
papers

1,834
citations

471477

17
h-index

526264

27
g-index

28
all docs

28
docs citations

28
times ranked

3035
citing authors

#	ARTICLE	IF	CITATIONS
1	Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma. <i>Cancers</i> , 2021, 13, 4422.	3.7	11
2	Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. <i>HemaSphere</i> , 2020, 4, e497.	2.7	14
3	<i>De novo</i> UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. <i>Haematologica</i> , 2019, 104, 1789-1797.	3.5	21
4	SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. <i>Nature Communications</i> , 2018, 9, 2192.	12.8	66
5	OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes. <i>Scientific Reports</i> , 2017, 7, 46290.	3.3	31
6	The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition. <i>Journal of Cancer</i> , 2017, 8, 140-145.	2.5	12
7	Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis. <i>Blood</i> , 2016, 128, 3075-3075.	1.4	1
8	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. <i>Blood</i> , 2015, 125, 499-503.	1.4	115
9	RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients. <i>American Journal of Hematology</i> , 2015, 90, E227-8.	4.1	2
10	BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene. <i>Molecular Cancer</i> , 2015, 14, 132.	19.2	35
11	ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents. <i>Oncotarget</i> , 2015, 6, 16611-16622.	1.8	18
12	Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. <i>Nature Genetics</i> , 2013, 45, 18-24.	21.4	359
13	Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex. <i>Neoplasia</i> , 2013, 15, 511-517.	5.3	44
14	Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases. <i>Molecular Genetics & Genomic Medicine</i> , 2013, 1, 246-259.	1.2	17
15	CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data. <i>PLoS ONE</i> , 2013, 8, e74825.	2.5	20
16	SETBP1 and CSF3R Mutations In Atypical Chronic Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2598-2598.	1.4	1
17	FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery. <i>Nucleic Acids Research</i> , 2012, 40, e123-e123.	14.5	29
18	Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2012, 87, E125-8.	4.1	93

#	ARTICLE	IF	CITATIONS
19	Integrated Analysis of Whole-Exome Sequencing and Micrnas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia. <i>Blood</i> , 2012, 120, 3727-3727.	1.4	1
20	ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells. <i>PLoS ONE</i> , 2011, 6, e28162.	2.5	25
21	Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. <i>Blood</i> , 2010, 116, 3013-3022.	1.4	110
22	Colorectal Tumors Are Effectively Eradicated by Combined Inhibition of β -Catenin, KRAS, and the Oncogenic Transcription Factor ITF2. <i>Cancer Research</i> , 2010, 70, 7253-7263.	0.9	45
23	Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants. <i>Journal of Clinical Oncology</i> , 2009, 27, 469-471.	1.6	365
24	Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. <i>International Journal of Cancer</i> , 2009, 124, 1990-1996.	5.1	29
25	The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 37, 111-115.	1.4	9
26	In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells. <i>Cancer Research</i> , 2006, 66, 11314-11322.	0.9	352
27	Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients. <i>Leukemia</i> , 2005, 19, 1985-1987.	7.2	9